Organisation paid for research Program year 2025 Source: CMS Open Payments

Mayo Clinic - Jacksonville

Neither a doctor nor a teaching hospital

Research payments

$386,596

68 payments

Through program year 2025, Mayo Clinic - Jacksonville is reported as receiving $386,596 in research payments, across 68 payments.

By program year

6 rows
Year Kind Amount Payments
2025 Research $101,215 5
2023 Research $99,417 2
2022 Research $20,000 1
2021 Research $40,746 21
2020 Research $122,116 38
2019 Research $3,102 1

Breakdown

Who paid Research payments · program years 2019–2025
  1. Astellas US Technologies $177,796 2 payments
  2. Allergan Inc. $141,163 54 payments
  3. Astellas Pharma Global Development $44,800 7 payments
  4. Adaptimmune LLC $22,539 3 payments
  5. E.R. Squibb & Sons, L.L.C. $273 1 payment
  6. Ucb SA $24 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. MC200505 Phase II Study of Enfortumab Vedotin Treatment for Metastatic Squamous Cell Carcinoma of the Penis $177,796 2 payments
  2. XEN-45 Gel Stent Versus Trabeculectomy in Glaucoma: Gold-Standard Pathway Study (GPS) $44,358 12 payments
  3. AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis $38,949 16 payments
  4. A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis $38,461 12 payments
  5. Randomized Trial of Gilteritinib vs Midostaurin in FL T3 Mutated Acute Myeloid Leukemia $34,000 4 payments
  6. Spearhead-1 $22,539 3 payments
  7. AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis $15,145 11 payments
  8. Randomized Trial of Gilteritinib VS Midostaurin in Flt3 Mutated Acute Myeloid Leukemia (Aml $10,800 3 payments
  9. AURORA A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis $3,102 1 payment
  10. The Efficacy and Safety of Bimatoprost SR in Patients With Open-angle Glaucoma or Ocular Hypertension $649 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record